Antimicrobial Resistance (AMR) Genotyping Panels Market Report 2026

The antimicrobial resistance (amr) genotyping panels market size has grown rapidly in recent years. It will grow from $1.45 billion in 2025 to $1.66 billion in 2026 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to rising prevalence of antimicrobial resistance, increased hospital-acquired infections, expansion of molecular diagnostic capabilities, growing awareness of resistance monitoring, availability of advanced genotyping technologies.

The antimicrobial resistance (amr) genotyping panels market size is expected to see rapid growth in the next few years. It will grow to $2.81 billion in 2030 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to increasing investments in infectious disease diagnostics, rising demand for rapid point-of-care testing, expansion of genomic epidemiology programs, growing integration of amr data analytics, increasing regulatory focus on resistance surveillance. Major trends in the forecast period include increasing adoption of multiplex resistance detection panels, rising use of rapid molecular diagnostics, growing integration of genomic surveillance tools, expansion of hospital-based amr testing, enhanced focus on early resistance identification.

The increasing prevalence of antimicrobial-resistant infections is expected to drive the growth of the antimicrobial resistance (AMR) genotyping panels market in the coming years. Antimicrobial-resistant infections are caused by microorganisms such as bacteria, viruses, fungi, or parasites that have evolved to withstand standard antimicrobial treatments, making infections harder to manage. Overuse and misuse of antibiotics are major contributors to the rise of resistance, accelerating the emergence of drug-resistant pathogens. AMR genotyping panels help combat this issue by rapidly identifying resistance genes and guiding targeted antimicrobial therapy. For instance, according to the Centers for Disease Control and Prevention (CDC), the US experiences over 2.8 million antimicrobial-resistant infections annually. Therefore, the increasing prevalence of antimicrobial-resistant infections is fueling the AMR genotyping panels market.

Companies in the AMR genotyping panels market are developing innovative molecular diagnostic solutions, such as multiplex PCR-based assays, to simultaneously detect multiple pathogens and resistance genes in a single test, improving research efficiency and enabling faster identification of emerging resistance patterns. Multiplex PCR-based assays are molecular tests that amplify and detect several genetic targets at once, allowing simultaneous identification of pathogens and their antibiotic-resistance markers. For example, in September 2025, Molecular Designs, a US-based molecular diagnostics company, launched the Urogenital Microbiota with ABX 53 Simplicity Panel. This multiplex PCR-based assay detects 28 urogenital and urinary microbial targets (20 bacterial, 7 fungal, and 1 protozoan) along with 25 antibiotic-resistance gene markers in a single test. It offers same-day results and is available in both 96-well and 384-well plate formats, with breakaway panels included in the 96-well version to reduce waste.

In June 2025, bioMérieux, a France-based provider of in vitro diagnostics systems, reagents, software, and infectious disease solutions, acquired the assets of Day Zero Diagnostics for $25 million. Through this acquisition, bioMérieux aimed to strengthen its next-generation sequencing (NGS) and rapid antimicrobial-resistance diagnostics capabilities to better address infectious diseases and AMR challenges. Day Zero Diagnostics, a US-based company, develops rapid whole-blood sample preparation, genome sequencing, and machine-learning analytics for pathogen identification and antibiotic-resistance profiling.

Major companies operating in the antimicrobial resistance (amr) genotyping panels market are Thermo Fisher Scientific Inc., F Hoffmann La Roche Ltd., Abbott Laboratories, Illumina Inc., bioMérieux SA., Bruker Corporation, QIAGEN NV., Cepheid Inc., Integrated DNA Technologies Inc., Seegene Inc., Oxford Nanopore Technologies plc., Streck Inc., MedGenome Inc., Vela Diagnostics Pte. Ltd., Agena Bioscience Inc., CD Genomics Inc., Curetis GmbH, T2 Biosystems Inc., 3B BlackBio Biotech India Ltd., Genefirst Ltd., OpGen Inc.

North America was the largest region in the antimicrobial resistance (AMR) genotyping panels market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antimicrobial resistance (amr) genotyping panels market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antimicrobial resistance (amr) genotyping panels market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the amr genotyping panels market by increasing costs of imported reagents, sequencing instruments, PCR consumables, microarrays, and bioinformatics hardware. Clinical laboratories in North America and Europe are most affected due to dependence on imported molecular diagnostic technologies, while Asia-Pacific faces higher costs in panel commercialization. These tariffs are increasing testing costs and slowing adoption in resource-limited settings. However, they are also supporting domestic diagnostic manufacturing, regional assay development, and localized supply chains for amr testing solutions.

The antimicrobial resistance (amr) genotyping panels market research report is one of a series of new reports that provides antimicrobial resistance (amr) genotyping panels market statistics, including antimicrobial resistance (amr) genotyping panels industry global market size, regional shares, competitors with a antimicrobial resistance (amr) genotyping panels market share, detailed antimicrobial resistance (amr) genotyping panels market segments, market trends and opportunities, and any further data you may need to thrive in the antimicrobial resistance (amr) genotyping panels industry. This antimicrobial resistance (amr) genotyping panels market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antimicrobial resistance (AMR) genotyping panels are advanced molecular diagnostic tools designed to detect, identify, and analyze genes responsible for antimicrobial resistance in bacteria and other pathogens. They allow simultaneous screening of multiple resistance markers, enabling faster and more accurate identification of resistant strains.

The main components of antimicrobial resistance (AMR) genotyping panels are custom panels and pre-designed panels. Custom AMR genotyping panels are tailored molecular test panels created to detect specific genetic markers conferring resistance in bacteria, viruses, or other pathogens. These panels use technologies such as polymerase chain reaction (PCR)-based methods, microarray-based platforms, next-generation sequencing (NGS), and others. They are applied in clinical diagnostics, research, drug development, and specialized studies. Key end-users include hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, and other healthcare and scientific organizations.

The antimicrobial resistance (AMR) genotyping panels market consists of sales of qPCR antimicrobial resistance detection kits, multiplex genotyping assays, next-generation sequencing reagent kits, antimicrobial resistance reference standards, and microarray slide kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.